RNA changes that influence brain damage after stroke
Role of RNAs in post-stroke brain damage
['FUNDING_OTHER'] · UNIVERSITY OF WISCONSIN-MADISON · NIH-11329543
Researchers aim to find how changes in different RNA molecules cause extra brain injury and identify ways to help people recover after a stroke.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WISCONSIN-MADISON (nih funded) |
| Locations | 1 site (MADISON, UNITED STATES) |
| Trial ID | NIH-11329543 on ClinicalTrials.gov |
What this research studies
This research looks at how chemical and epigenetic changes to RNAs after an ischemic stroke contribute to secondary brain damage and slower recovery. The team will study long noncoding RNAs and RNA chemical marks such as DNA hydroxymethylation (5hmC) and N6-methyladenosine using lab models and molecular techniques to map where these changes happen. They plan four linked projects that include continuing prior work on 5hmC in lncRNAs, mapping RNA modifications, and testing whether altering these marks changes cell survival and function. If successful, the work should point to specific RNA-related targets that could be turned into drugs or other therapies to protect the brain after stroke.
Who could benefit from this research
Good fit: People who have had an ischemic (blood-flow) stroke—especially in the acute or early recovery phase—would be the most relevant candidates for future treatments arising from this research.
Not a fit: People with hemorrhagic stroke, strokes many years in the past, or whose care does not involve RNA-targeted treatments may not see direct benefits from this basic lab-focused project.
Why it matters
Potential benefit: Could point to new RNA-related drug targets or therapies that reduce secondary brain damage and improve recovery after stroke.
How similar studies have performed: Previous preclinical studies suggest that modifying RNA marks can change neuronal survival, but translating these findings into human treatments is still largely experimental.
Where this research is happening
MADISON, UNITED STATES
- UNIVERSITY OF WISCONSIN-MADISON — MADISON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VEMUGANTI, RAGHU — UNIVERSITY OF WISCONSIN-MADISON
- Study coordinator: VEMUGANTI, RAGHU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired brain injury